earnings
confidence high
sentiment positive
materiality 0.65
Balchem Q1 net sales $270.7M (+8.1%); adjusted EBITDA $74.3M (+12.1%)
BALCHEM CORP
2026-Q1 EPS reported
$1.25
revenue$270,709,000
- Net sales $270.7M, up 8.1% YoY; GAAP EPS $1.25, adjusted EPS $1.33.
- Adjusted EBITDA $74.3M (+12.1%); free cash flow $33.8M; operating cash flow $40.1M.
- All three segments posted sales and earnings growth; record Q1 net sales, EBITDA, and net earnings.
- New clinical fMRI study on VitaCholine suggests cognitive health benefits in post-menopausal women.
- CEO cites strong business model resilience; no guidance change despite geopolitical and trade uncertainty.